巴瑞替尼治疗幼年特发性关节炎相关葡萄膜炎或慢性前部抗核抗体阳性葡萄膜炎的临床有效性与安全性:开放标签、阿达木单抗阳性对照3期临床试验方案(JUVE-BRIGHT)
本研究为多中心3期开放标签贝叶斯设计试验,纳入至少20至最多40例2至<18岁活动性JIA相关葡萄膜炎或无全身表现的慢性ANA阳性葡萄膜炎患者。至少20例MTX-IR但未使用bDMARD者按1:1随机接受巴瑞替尼或阿达木单抗,另约20例MTX-IR或bDMARD应答不佳者接受巴瑞替尼。主要终点为第24周应答患者比例,评估巴瑞替尼的有效性与安全性。
要点
- 巴瑞替尼按年龄固定剂量口服:≥6至<18岁4 mg,<6岁2 mg,每日一次。
- 阿达木单抗每2周皮下注射:<30 kg 20 mg,≥30 kg 40 mg。
- 主要终点为第24周应答患者比例,治疗可持续至5年。
核心结论
- 这是首个评估JAK抑制剂治疗JIA相关葡萄膜炎或慢性ANA阳性葡萄膜炎的儿科临床试验。
- 采用贝叶斯设计评估巴瑞替尼有效性,并设阿达木单抗参考臂。
研究设计与样本
- 多中心3期开放标签贝叶斯设计试验。
- 计划纳入至少20至最多40例2至<18岁活动性JIA相关葡萄膜炎或无全身表现的慢性ANA阳性葡萄膜炎患者。
- 至少20例MTX-IR但未使用bDMARD者按1:1随机接受开放标签巴瑞替尼或阿达木单抗。
- 另约20例MTX-IR或bDMARD应答不佳者接受巴瑞替尼治疗。
- 允许稳定背景csDMARD、低剂量糖皮质激素和/或NSAIDs治疗。
关键数值与推荐
- 巴瑞替尼固定剂量按年龄分组:≥6至<18岁4 mg,<6岁2 mg,每日一次口服。
- 阿达木单抗剂量:<30 kg 20 mg,≥30 kg 40 mg,每2周皮下注射。
- 主要终点为第24周应答患者比例。
- 患者可继续治疗至5年。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disease and the most common systemic disorder associated with uveitis in childhood. Uveitis is more common in JIA patients who are antinuclear antibody (ANA)-positive, have an early-onset disease, and have oligoarticular arthritis. JIA-associated uveitis (JIA-uveitis) is typically anterior, chronic, bilateral, nongranulomatous, and asymptomatic. Visual outcomes in JIA-uveitis have improved with current screening and treatment options; however, many patients fail to respond or do not achieve long-lasting remission. Baricitinib, an oral selective Janus kinase (JAK)1 and 2 inhibitor, may impact key cytokines implicated in the pathogenesis of JIA-uveitis or ANA-positive uveitis, representing a potential novel treatment option for disease management. METHODS: The multicenter, phase 3 trial will be conducted using an open-label Bayesian design. The study will enroll at least 20 and up to 40 patients aged 2 to <18 years with active JIA-uveitis or chronic ANA-positive uveitis without systemic features. At least 20 patients who have had an inadequate response or intolerance to methotrexate (MTX-IR), but not biologic disease-modifying antirheumatic drugs (bDMARDs), will be randomized (1:1) to open-label baricitinib or adalimumab. Approximately 20 additional patients who are MTX-IR or bDMARD inadequate responders will receive baricitinib treatment. Patients will be treated with once daily oral baricitinib at a fixed dose by age group (4 mg for patients aged ≥6 to <18 years and 2 mg for patients <6 years) or adalimumab (20 mg for patients weighing <30 kg and 40 mg for patients ≥30 kg) as a subcutaneous injection every 2 weeks. Treatment with stable background conventional synthetic DMARDs, low-dose corticosteroids, and/or nonsteroidal anti-inflammatory drugs is allowed. The primary endpoint is the proportion of patients with response at week 24. Patients may continue treatment for up to 5 years. DISCUSSION: This is the first pediatric clinical trial to assess the clinical effectiveness and safety of a JAK inhibitor in JIA-uveitis or chronic ANA-positive uveitis. A novel Bayesian design is used to assess the efficacy of baricitinib, including an adalimumab reference arm, in this small patient population with unmet medical need. TRIAL REGISTRATION: EudraCT 2019-000119-10 . Registered on January 4, 2019; NCT04088409 . Registered on September 12, 2019.
引用
- Ramanan AV, Guly CM, Keller SY, et al. Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT). Trials. 2021. PMID: 34627340. doi:10.1186/s13063-021-05651-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。